Status: Recruiting
Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia
This prospective, single center, single-arm study aims to evaluate the efficacy and safety of anti-human T lymphocyte porcine immunoglobulin (p-ALG) in combination with cyclosporine and Romiplostim in treating severe aplastic anemia (SAA). It will include 48 patients with newly diagnosed SAA.
Participants needed: 48
Trial details
Phase: Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: Institute of Hematology & Blood Diseases Hospital, ChinaUpdated: Dec 4, 2024Locations: 1
Eligibility criteria
Age ≥ 12 years [+4]
Received > 4 weeks of TPO-RA drug before treatment [+11]